ATRA

10.26

5.70% -0.62

Handel nachbörslich: 10.28 0.02 +0.19%

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$10.88

Offen:

$10.96

24-Stunden-Volumen:

49,325

Relative Volume:

0.04

Marktkapitalisierung:

$92.44M

Einnahmen:

$23.14M

Nettoeinkommen (Verlust:

$-9.47M

KGV:

-11.62

EPS:

-0.8827

Netto-Cashflow:

$-25.88M

1W Leistung:

-10.63%

1M Leistung:

+3.43%

6M Leistung:

-31.33%

1J Leistung:

+19.58%

1-Tages-Spanne:

$10.26

$10.99

1-Wochen-Bereich:

$10.26

$12.00

52-Wochen-Spanne:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1094)

Branche

Biotechnology (615)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	10.26	98.03M	23.14M	-9.47M	-25.88M	-0.8827
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Herabstufung	Canaccord Genuity	Buy → Hold
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Jul 06, 2026

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Jul 06, 2026

Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3 - Stock Titan

Jul 06, 2026

Jul 05, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 05, 2026

Jul 03, 2026

ATRAAtara Biotherapeutics Inc Latest SEC Filings - Finviz

Jul 03, 2026

Jul 02, 2026

ATRA Stockholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review

Jul 02, 2026

Jun 30, 2026

Discipline and Rules-Based Execution in ATRA Response - Stock Traders Daily

Jun 30, 2026

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Jun 30, 2026

ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jun 30, 2026

ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jun 30, 2026

Jun 28, 2026

Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 28, 2026

Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20) - TradingView

Jun 28, 2026

Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Atara Biotherapeutics Inc Actuals & Estimates (SWB:AT20) - TradingView

Jun 26, 2026

ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill

Jun 26, 2026

Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO - Stock Titan

Jun 26, 2026

Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA) - TradingView

Jun 26, 2026

Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jun 25, 2026

ATRA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 25, 2026

Jun 24, 2026